Product
Recombinant COVID-19 Vaccine (Sf9 Cell)
2 clinical trials
1 indication
Indication
COVID-19Clinical trial
Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster Following Primary Vaccination of Either Inactivated or mRNA or Viral Vector COVID-19 VaccinesStatus: Completed, Estimated PCD: 2022-08-18
Clinical trial
A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster in People Aged 18-60 YearsStatus: Completed, Estimated PCD: 2023-03-29